An investigative deep dive into Zycal Bioceuticals’ false bone growth supplement claims, capitalism’s broken promises, and the economic fallout for communities.

In early 2020, the Federal Trade Commission (FTC) filed a complaint against ZyCal Bioceuticals Healthcare Company, Inc. and its principal, as well as other associated parties, alleging a far-reaching scheme of deceptive health claims and undisclosed conflicts of interest. At the heart of this complaint lay some of the most damning evidence of corporate misconduct in the nutritional supplement industry: documents and advertisements that promised miraculous “bone growth” and “cartilage regeneration” without any reliable scientific proof. The FTC alleged that the Zycal Bioceuticals exploited testimonials from employees posing as ordinary consumers, circulated unverified clinical research, and manipulated consumers into believing they would overcome debilitating joint pain simply by taking these supplements.

These allegations are especially troubling because they reveal a pattern of behavior in which profit-making and marketing flair allegedly trump actual evidence or consumer well-being. According to the complaint, ZyCal Bioceuticals used its flagship ingredient, known as “Cyplexinol,” to claim that products like “StimTein” and “Ostinol” could regrow human bone and cartilage—even in people suffering from serious disorders such as osteoporosis, osteopenia, and arthritis. The complaint further alleges these companies systematically enticed buyers with statements about “cutting-edge science,” “40 years of research,” “clinically proven” results, and personal success stories that turned out to be from company insiders.

Yet, as the FTC declared, these sweeping health assurances rested on a bedrock of unsubstantiated claims rather than rigorous scientific evidence. The result, according to the Commission, was that consumers placed their confidence—and often their health—in the hands of a corporate operation that lacked proof for its sensational promises. Beyond the misdeeds of ZyCal Bioceuticals and its partners, this case illuminates how some segments of the dietary supplement industry navigate regulatory gaps. It also underscores deeper systemic issues under neoliberal capitalism—namely how the pressures of deregulation, regulatory capture, and relentless profit-maximization can create fertile ground for harmful, misleading marketing.

The following investigative article will delve into these allegations, highlighting the key details found in the FTC’s legal docs, while also examining their broader significance in the context of corporate social responsibility, corporate corruption, and the economic fallout inflicted on consumers and communities. Although the impetus for this exposé is a single legal complaint, the patterns it reveals parallel other corporate scandals in healthcare, consumer goods, and beyond. Ultimately, this narrative explores how an alleged scheme in the supplement sector can be symptomatic of a larger ecosystem of corporate greed, failing regulations, and rising wealth disparity, all fueling the machine of neoliberal capitalism.

---

Corporate Intent Exposed

The FTC’s legal filing depicts a situation wherein ZyCal Bioceuticals and affiliated marketers, rather than focusing on actual scientific inquiry, funneled their resources into bold marketing slogans. The complaint states that the company systematically conflated preliminary or irrelevant studies with “clinically proven” results, then splashed those claims across infomercials, websites, and brochures. Pointing to repeated references to “Bone Activating Proteins,” “40 years of research,” and “proven in prestigious medical journals,” the FTC claims that ZyCal Bioceuticals presented mere conjecture as established fact.

Product Claims and Their Alleged Lack of Evidence

One of the most startling parts of the complaint lies in its detailed breakdown of how certain statements—like “rebuild bone density in just weeks” or “stimulate your body’s ability to grow cartilage in days”—were completely unsupported by the rigorous human clinical trials that such far-reaching claims would require. Although the advertisements name-dropped recognized journals (e.g., The Journal of Biological Chemistry, among others), the FTC alleged that none of these references actually confirmed that ingestible Cyplexinol could regrow cartilage or heal bone in consumers.

These allegations point to something more than just a marketing slip-up. Instead, the complaint describes a business strategy meticulously orchestrated to win consumer trust and siphon money from a vulnerable demographic. People suffering from bone and joint issues—arthritis, osteoporosis, degenerative conditions—often seek alternative solutions when conventional medicine fails to give them immediate relief. According to the FTC, the defendants preyed on this desperation with sweeping statements designed to captivate and encourage quick sales.

Undisclosed Endorsements

Another detail in the FTC’s complaint that underscores the companies’ alleged intent centers on testimonials. Several “user stories” depicted dramatic transformations—testimonials that insisted on near-miraculous improvements in mobility and pain relief. Yet, the complaint states these endorsements turned out to be from employees and close associates, contradicting the portrayal of impartial user feedback.

Their titles, backgrounds, and ties to the company were never disclosed, effectively turning a marketing campaign into a staged, and possibly deceptive, performance. The giant gap between how these testimonies were presented—as impartial user experiences—and the actual reality that they were company insiders exemplifies the broader manipulations that the FTC claims the firm was willing to make.

The Larger Strategic Pattern

Taken together, these allegations point to a strategy built on packaging normal dietary supplements with science-y language and doctor-like endorsements. The complaint lays bare that none of this was verified by neutral academic institutions or robust clinical studies. Instead, the project was orchestrated by managers, marketers, and potentially complicit scientists or advisors, who each, as the FTC suggests, contributed their piece to ensure an all-too-convincing but ultimately deceptive narrative.

In an environment shaped by neoliberal capitalism, where self-regulation or minimal regulation can make it easy for questionable claims to slip through the cracks, the alleged intent behind this campaign stands as a grim testament to the profound imbalance between corporate power and consumer protection.

---

The Corporations Get Away With It

Standing back from the product-level claims, the complaint also illuminates one question: How did they manage to get away with such bold marketing? The short answer is that, per the FTC, they leveraged loopholes inherent in the dietary supplement industry. The long answer traces back to decades of legislative adjustments and regulatory philosophies, especially in the United States, that have allowed corporations more leeway to structure their health claims in ways that outpace enforcement.

Legal and Regulatory Blind Spots

Although the FDA and FTC collectively oversee the marketing of health-related products, the resources required to police every single supplement manufacturer are enormous. Meanwhile, the user-defined disclaimers—often limited to “This statement has not been evaluated by the FDA”—do not adequately shield consumers from false confidence. The FTC complaint contends that ZyCal Bioceuticals exploited these regulatory cracks by plastering their packaging, infomercials, and websites with arcane references to “studies” or “medical usage,” effectively overshadowing disclaimers.

When a company invests significant sums in marketing, from celebrity endorsements to “doctor recommended” infomercials, it can create a critical mass of consumer belief before regulators can move in. Sometimes, it takes months or years for regulatory bodies to secure enough evidence to file a complaint. This delayed reaction is a hallmark feature of neoliberal capitalism: the belief that markets will self-correct can place undue burdens on enforcement, leading to corporate accountability failures.

The Infomercial Machine

The defendants allegedly also made heavy use of the infomercial ecosystem—a realm notorious for high-decibel health promises. Infomercials typically do not undergo robust fact-checking prior to airtime (unlike, say, a strict peer-reviewed medical publication). As a result, the distributors of the programming have little immediate incentive to scrutinize claims. By the time consumer complaints or regulatory investigations surface, a brand can rake in millions.

According to the FTC, ZyCal Bioceuticals partnered with promotional experts who recognized this approach. Their channels included internet marketing, direct mail, and even radio or short-form television spots. This matrix of communication ensured that the average consumer was exposed to a consistent, single message: “Our product is scientifically proven to restore your joints and bones, quickly and safely.” By the time reality set in for consumers—often after repeated monthly purchases or increasing credit card bills—the companies had already profited immensely.

---

The Cost of Doing Business

One concept that emerges vividly from the FTC complaint is what might be called the “cost of doing business”. Even if a corporation faces legal liability or reputational setbacks from deceptive marketing, the potential returns from such conduct can dwarf any penalties—especially when there are no criminal repercussions at stake. In the ZyCal case, the complaint details millions in gross sales over a span of years. Even if a settlement or court ruling imposes fines or restitution, the net gain might still be significant for unscrupulous operators, if they planned it all carefully.

Financial Windfall vs. Consumer Loss

On one side, the companies allegedly reaped substantial revenues by telling consumers exactly what they wanted to hear. On the other side, real people—many in pain or anxious about their health—wasted money on unproven products, losing time, trust, and the chance to pursue evidence-based treatments. For older consumers on fixed incomes, the cost could be especially devastating. And while the defendants may argue “no one is forced to buy these products,” the marketing materials’ repeated references to “clinically proven results” have, according to the FTC, the power to sway consumers’ decisions.

The Economic Fallout on Communities

When misleading products proliferate in the market, the damage extends beyond individual pocketbooks. Medical costs rise when patients delay legitimate treatments. Trust in healthcare professionals weakens when hype-fueled marketing saturates the environment. In communities where a large proportion of residents are elderly or otherwise vulnerable, the local economy may absorb the impact via increased healthcare burdens and reduced disposable income.

Such local-level economic fallout speaks to corporate accountability issues that ripple through the entire system. If a business model thrives simply by creating illusions of medical breakthroughs, it disrupts real innovation and fosters cynicism about the scientific process. In the broader ecosystem of neoliberal capitalism, such cynicism can dangerously erode the credibility of regulatory bodies.

---

Systemic Failures

Allegations of false advertising and corporate misconduct tend to provoke simple questions: Where were the regulators? Why didn’t they intervene sooner? The ZyCal Bioceuticals case, as laid out in the FTC complaint, underscores how systemic failures of oversight are more than a matter of resources. They also reflect deeply rooted policies and philosophies about how markets should function.

Deregulation Under Neoliberal Capitalism

Over the last few decades, a neoliberal approach to governance, championing free markets and minimal regulatory interference, has shaped a variety of industries, including dietary supplements. Under this philosophy, corporations often enjoy the benefit of the doubt. The assumption is that customers will “vote with their wallets,” that reputational forces will discipline businesses, and that direct government intervention will be minimal.

Yet the FTC’s allegations regarding ZyCal Bioceuticals’ practices illustrate how reputational constraints can fail. After all, to “vote with their wallets,” consumers need accurate information. If the available “information” has been stage-managed to promise near-miraculous cures, and if skeptics must wade through an ocean of marketing spin, then the entire premise of free-market accountability falters.

Regulatory Capture and Corporate Influence

In parallel, regulatory capture, in which corporate interests exercise undue sway over the agencies meant to oversee them, is another aspect of the neoliberal landscape. While there is no direct claim in the complaint that ZyCal or its affiliates manipulated policy, the lawsuit’s existence suggests the limits of the system. Regulators like the FTC are forced to pick their battles, often entering the scene after harm is done. Meanwhile, the companies in question can claim plausible deniability—arguing that they never intentionally deceived anyone, or that they believed their internal “research” was valid.

Systemic failure thus emerges not from a single point of breakdown, but from a synergy of corporate lobbying, lenient legislative frameworks, and bureaucratic constraints that hamper timely and decisive enforcement action. In the space left by these compromised structures, allegations of corporate corruption and corporate greed can more easily flourish.

---

This Pattern of Predation Is a Feature, Not a Bug

The allegations against ZyCal Bioceuticals do not stand alone. Past decades have seen repeated FTC and FDA actions against supplement manufacturers for making baseless claims about curing diseases, restoring youth, or supercharging the immune system. Why do we keep seeing these controversies erupt with such regularity?

A cynical but arguably accurate answer is that the underlying system is designed in such a way that fosters an environment ripe for these behaviors. High profit margins on nutritional supplements, combined with consumers’ persistent search for miracle cures, create a huge incentive for unscrupulous business tactics. The cyclical pattern— questionable claims, big profits, possible lawsuits, moderate penalties, and then rebranding—is, for some players, simply the cost of doing business.

Tying It to Wealth Disparity and Corporate Greed

When corporations can monetize consumers’ pain, confusion, and vulnerability, the result can be an ever-widening wealth disparity. Executives and shareholders reap significant rewards, while marginalized individuals and communities struggle to combat chronic ailments or limited incomes. The ZyCal Bioceuticals complaint, in describing a product pitched to older adults or those with degenerative bone diseases, highlights how a population that is already medically and financially stressed can be rendered even more precarious.

This pattern of predation—presented as normal market behavior—is not a glitch in the neoliberal system. Indeed, from a certain perspective, it is functioning as intended: minimal constraints on corporate activity, maximum leeway for “innovation,” and the relegation of consumer protection to an after-the-fact mechanism of enforcement.

---

The PR Playbook of Damage Control

When corporate wrongdoing surfaces—be it in the form of a government complaint, a whistleblower disclosure, or media investigation—there is often a well-trodden script for damage control. Although ZyCal Bioceuticals may present itself as cooperative or vow to “refine” its marketing, it is essential to note how the broader PR tactic typically unfolds.

Step 1: Denial and Minimization

In many cases, companies begin with denial, either that no wrongdoing occurred or that the allegations are a result of misunderstanding. Although the FTC complaint references specific claims—like “growing cartilage in days” or “backed by 40 years of research”—the standard corporate line might be that these statements were “misinterpreted by regulators.”

Step 2: Emphasize ‘No Harm, No Foul’

Even when forced to concede some marketing missteps, companies frequently portray the harm as negligible. In the supplement arena, the retort is often that there were “no documented injuries,” so the emphasis is placed on intangible “benefits” that can’t easily be disproven. Yet, if we consider the economic and emotional harm done to consumers who banked on these unproven solutions, we see how insidious this approach can be.

Step 3: Quick Settlements and Rebranding

Many corporations facing FTC actions opt to settle—agreeing to permanent injunctions, changing labeling, or paying specific penalties. Yet this settlement process can become part of the cycle: rebrand, retool the marketing, then release new products. Even if the original brand is tainted, the underlying corporate structure can remain intact, and the same marketing personnel can simply shift tactics.

By employing this predictable set of PR tactics, the corporation works to control the narrative. In a system that prioritizes continuous growth and shareholder returns above all else, such cyclical crises and short-lived penances appear to be a standard operating procedure.

---

Corporate Power vs. Public Interest

At its core, the FTC’s complaint against ZyCal Bioceuticals underscores a struggle between corporate power and public interest. How do we uphold corporate social responsibility when the impetus to accumulate profits is so strong that it can eclipse ethical considerations?

Weakening Regulatory Shields

The interplay between corporate lobbying and legislative policymaking effectively removes or reduces oversight teeth. Dietary supplements, in particular, exist in a regulatory gray zone. According to policy experts, the bar for proving a supplement’s efficacy is lower than that for pharmaceuticals, partly thanks to lobbying by industry groups that claim innovation would be stifled by tougher requirements. This delicate regulatory environment can become an invitation for opportunistic entities to experiment with wild, unverified claims until someone complains loudly enough or a government body steps in.

Undermining Corporate Social Responsibility

The repeated references in advertisements to “growing cartilage” or “strengthening bone in days” do more than just distort scientific fact; they degrade trust in corporate ethics. Consumers who discover they’ve been misled by one supplement brand may lose faith in the entire wellness industry. Small, genuinely innovative businesses end up tarred with the same brush. Meanwhile, the big players who have resources to handle legal pushback remain in an advantageous position, effectively creating a market environment that punishes honesty and rewards those who can best navigate (or exploit) ambiguous claims.

Potential Dangers to Public Health

Although these are not pharmaceuticals designed to treat cancer or heart disease, the issue still intersects with public health. People who rely on unproven supplements to manage severe arthritic conditions might delay or entirely forgo evidence-based medical interventions. The cumulative effect of such decisions can be significant, leading to worsened physical conditions and higher eventual healthcare costs. In these ways, the allegations connect directly to the notion of corporations’ dangers to public health, underscoring how profit-chasing can overshadow legitimate care for consumer well-being.

---

The Human Toll on Workers and Communities

Too often, the conversation focuses on the direct consumer who invests in a possibly ineffective supplement. Yet the human toll can be broader and more layered. As the FTC’s complaint notes, these products were sold at premium prices to populations already grappling with challenging conditions such as osteoporosis or chronic arthritis. In many communities, especially those with limited access to specialized healthcare, these alleged false promises might have become a perceived lifeline.

Strain on Local Economies and Individuals

Individuals who spend money on unsubstantiated products often have less to invest in legitimate medical therapies, local businesses, or community services. The ripple effect might be especially pronounced among older populations on fixed incomes. A monthly supply costing $45 to $135 can quickly become burdensome if purchased over months or years in pursuit of a nonexistent “miracle cure.”

Emotional and Psychological Costs

Beyond the dollars and cents, these allegations carry emotional resonance. False hope, followed by disappointment, can devastate a person’s morale. Individuals in pain may suffer further as they realize they were lured in by illusions. A general erosion of trust in businesses, in healthcare professionals, and in one’s own ability to discern truth from advertising can also emerge.

Worker Perspectives

Though the complaint focuses on the marketing tactics, it also raises questions about the corporate culture in which employees may have found themselves compelled to give glowing endorsements of a product without disclosing that they were on the payroll. Such practices can degrade the sense of professional integrity and potentially coerce workers into becoming complicit in questionable, if not fraudulent, activities. The fear of job loss or lack of viable alternatives might pressure individuals to comply, contributing to the cyclical nature of unethical corporate structures.

---

Global Trends in Corporate Accountability

While this case is rooted in the United States, the underlying dynamics—companies leveraging regulatory blind spots to maximize profits—can be seen worldwide. Neoliberal capitalism is, by definition, a global phenomenon, and many nations wrestle with balancing free-market policies against corporate accountability.

Deregulated Supplement Markets Abroad

Regions with limited oversight on dietary supplements—whether due to weaker laws, limited enforcement budgets, or corporate capture of regulations—can see a proliferation of these same issues: unverified health claims, shady endorsements, and a huge marketing machine that dwarfs the capacity of local agencies. In some cases, products found unlawful in one country are simply repackaged and sold in another, reflecting a pattern of corporate opportunism that transcends borders.

Consumer Advocacy Movements

Amid these growing tensions, consumer advocacy networks—both grassroots and formally organized—have become increasingly vocal. Groups that champion consumer rights raise alarms about questionable scientific claims, petition legislators, and use social media to rapidly spread warnings about suspect products. In some instances, international coalitions coordinate to push for standardized regulations that demand robust clinical evidence before a product can be advertised with disease-related claims.

If there is a silver lining to repeated controversies, it is the increased global collaboration among advocacy groups. This synergy exerts pressure on corporations to meet higher ethical benchmarks. While progress is uneven, each high-profile lawsuit or FTC complaint becomes a rallying cry, illustrating that these patterns of corporate greed and unscrupulous marketing remain widespread and require concerted action.

---

Pathways for Reform and Consumer Advocacy

In the end, the complaint against ZyCal Bioceuticals underscores how a single corporate action—allegedly false health claims—can highlight fundamental systemic flaws. Reform can take various paths, each shaped by the tension between the ideals of free enterprise and the realities of corporate accountability.

1. Stronger Regulatory Oversight

One potential solution is stricter governmental oversight of dietary supplements. If companies were required to demonstrate a higher level of scientific substantiation before making claims, the market would likely see far fewer “miracle cures.” Some advocates even propose an approval or certification process akin to what pharmaceuticals must undergo. Of course, this approach would stifle innovation and raise costs, but others respond that genuine innovation requires verifiable science, not marketing smoke and mirrors.

2. Heightened Penalties

A consistent theme in cases of corporate misconduct is whether the penalties inflicted are severe enough to deter future wrongdoing. If fines and settlements do not sufficiently cut into a company’s profits, they become just another line item—absorbed as a business expense. Legislation that pegs fines to a percentage of total revenue, or that includes personal liability for executives who authorize false claims, could shift the cost-benefit calculus.

3. Consumer Education and Empowerment

In a market environment flush with advertisements, consumer education is a powerful tool. Knowing how to distinguish legitimate scientific backing from marketing hype can protect individuals from potential scams. Media campaigns, official FTC consumer advisories, and private initiatives all help foster this understanding. In parallel, consumer advocacy lawsuits—class actions, for instance—can empower individuals to challenge deceptive claims.

4. Corporate Culture Reforms

A deeper, more systemic change requires transforming corporate cultures that reward aggressive sales quotas while ignoring or punishing employees who question marketing tactics. Whistleblower protections, robust codes of conduct, and transparency about product testing and research partnerships can all help realign incentives. Encouraging a model of corporate social responsibility that values public well-being as a genuine business objective—rather than a marketing slogan—could gradually shift the broader landscape.

5. Grassroots and Policy Activism

Finally, individuals and communities can push beyond consumer complaints toward activism that demands legislative changes. Whether it involves lobbying for more oversight, pressuring legislators to reject corporate donations that compromise impartial policy decisions, or advocating for public health measures, grassroots campaigns have historically played a key role in reining in unscrupulous corporate conduct.

---

The FTC has a couple of links about this story, this is the most recent as of today: https://www.ftc.gov/system/files/documents/cases/182_3133_zycal_bio_-_stipulated_final_order_0.pdf

💡 Explore Corporate Misconduct by Category

Corporations harm people every day — from wage theft to pollution. Learn more by exploring key areas of injustice.

• 💀 Product Safety Violations — When companies risk lives for profit.
• 🌿 Environmental Violations — Pollution, ecological collapse, and unchecked greed.
• 💼 Labor Exploitation — Wage theft, worker abuse, and unsafe conditions.
• 🛡️ Data Breaches & Privacy Abuses — Misuse and mishandling of personal information.
• 💵 Financial Fraud & Corruption — Lies, scams, and executive impunity.

NOTE:

This website is facing massive amounts of headwind trying to procure the lawsuits relating to corporate misconduct. We are being pimp-slapped by a quadruple whammy:

1. The Trump regime's reversal of the laws & regulations meant to protect us is making it so victims are no longer filing lawsuits for shit which was previously illegal.
2. Donald Trump's defunding of regulatory agencies led to the frequency of enforcement actions severely decreasing. What's more, the quality of the enforcement actions has also plummeted.
3. The GOP's insistence on cutting the healthcare funding for millions of Americans in order to give their billionaire donors additional tax cuts has recently shut the government down. This government shut down has also impacted the aforementioned defunded agencies capabilities to crack down on evil-doers. Donald Trump has since threatened to make these agency shutdowns permanent on account of them being "democrat agencies".
4. My access to the LexisNexis legal research platform got revoked. This isn't related to Trump or anything, but it still hurt as I'm being forced to scrounge around public sources to find legal documents now. Sadge.

All four of these factors are severely limiting my ability to access stories of corporate misconduct.

Due to this, I have temporarily decreased the amount of articles published everyday from 5 down to 3, and I will also be publishing articles from previous years as I was fortunate enough to download a butt load of EPA documents back in 2022 and 2023 to make YouTube videos with.... This also means that you'll be seeing many more environmental violation stories going forward :3

Thank you for your attention to this matter,

Aleeia (owner and publisher of www.evilcorporations.com)

Also, can we talk about how ICE has a $170 billion annual budget, while the EPA-- which protects the air we breathe and water we drink-- barely clocks $4 billion? Just something to think about....